Multicenter, retrospective, and observational study of afatinib treatment in patients with non-small cell lung cancer harboring EGFR mutation who previously treated with EGFR-TKI.

Trial Profile

Multicenter, retrospective, and observational study of afatinib treatment in patients with non-small cell lung cancer harboring EGFR mutation who previously treated with EGFR-TKI.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2015

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Sep 2015 Status changed from not yet recruiting to discontinued,as reported by University Hospital Medical Information Network - Japan record.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top